{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:30:57Z","timestamp":1780486257035,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81371798"],"award-info":[{"award-number":["81371798"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Biomarkers for early diagnosis of hepatocellular carcinoma (HCC) are needed in chronic hepatitis B virus (HBV) infection, a leading cause of HCC. We evaluated whether measurement of serum pentraxin 3 (PTX3) could improve diagnosis of HCC in chronic HBV infection. Data from patients with HBV-related chronic hepatitis (n\u2009=\u2009159), cirrhosis (n\u2009=\u200999) and HCC (n\u2009=\u2009107), and healthy controls (n\u2009=\u2009151) were analyzed. Serum PTX3 concentration was measured by immunoassay. Area under the receiver operating characteristic curve (AUC) was applied to assess diagnostic accuracy. PTX3 levels were significantly higher in HBV patients than in healthy controls (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and in HCC than in chronic hepatitis (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) or cirrhosis patients (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). PTX3 was an independent risk factor of HCC [odds ratio (OR) 1.617,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001] and could distinguish HCC in chronic HBV infection [cutoff 9.231\u00a0ng\/mL, AUC 0.929 with 95% confidence interval (CI) of 0.898\u20130.953], including \u03b1-fetoprotein (AFP) negative [cutoff 8.985\u00a0ng\/mL, AUC (95%CI) 0.947 (0.908\u20130.973)] and early-stage HCC [cutoff 9.359\u00a0ng\/mL, AUC (95%CI) 0.920 (0.885\u20130.947)]. Combination of PTX3 with AFP improved the discrimination of early HCC from chronic HBV infection [AUC (95%CI) 0.948 (0.918\u20130.970)]. In short, PTX3 measurement could identify HCC, including AFP-negative and early-stage HCC, in chronic HBV infection.<\/jats:p>","DOI":"10.1038\/s41598-020-77332-3","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T11:11:54Z","timestamp":1605870714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection"],"prefix":"10.1038","volume":"10","author":[{"given":"Huan","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiude","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"issue":"6","key":"77332_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"77332_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1053\/j.gastro.2003.12.049","volume":"126","author":"A Sangiovanni","year":"2004","unstructured":"Sangiovanni, A. et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126(4), 1005\u20131014 (2004).","journal-title":"Gastroenterology"},{"issue":"3","key":"77332_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bpg.2017.05.008","volume":"31","author":"MS Chang","year":"2017","unstructured":"Chang, M. S. & Nguyen, M. H. Epidemiology of hepatitis B and the role of vaccination. Best Pract. Res. Clin. Gastroenterol. 31(3), 239\u2013247 (2017).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"10003","key":"77332_CR4","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G. & Ott, J. J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386(10003), 1546\u20131555 (2015).","journal-title":"Lancet"},{"issue":"9963","key":"77332_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963), 117\u2013171 (2015).","journal-title":"Lancet"},{"issue":"10","key":"77332_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJM199903113401001","volume":"340","author":"HB El-Serag","year":"1999","unstructured":"El-Serag, H. B. & Mason, A. C. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340(10), 745\u2013750 (1999).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"77332_CR7","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.18632\/oncotarget.2913","volume":"6","author":"Q Zhu","year":"2015","unstructured":"Zhu, Q. et al. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget 6(6), 4440\u20134450 (2015).","journal-title":"Oncotarget"},{"issue":"9822","key":"77332_CR8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379(9822), 1245\u20131255 (2012).","journal-title":"Lancet"},{"issue":"2","key":"77332_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/hep.510310211","volume":"31","author":"MF Yuen","year":"2000","unstructured":"Yuen, M. F. et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 31(2), 330\u2013335 (2000).","journal-title":"Hepatology"},{"issue":"5","key":"77332_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/MAJ.0000000000000200","volume":"347","author":"MG Shoreibah","year":"2014","unstructured":"Shoreibah, M. G., Bloomer, J. R., McGuire, B. M. & Massoud, O. I. Surveillance for hepatocellular carcinoma: evidence, guidelines and utilization. Am. J. Med. Sci. 347(5), 415\u2013419 (2014).","journal-title":"Am. J. Med. Sci."},{"issue":"8","key":"77332_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1470-2045(12)70271-1","volume":"13","author":"A Forner","year":"2012","unstructured":"Forner, A. & Bruix, J. Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol. 13(8), 750\u2013751 (2012).","journal-title":"Lancet Oncol."},{"issue":"2","key":"77332_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s12253-019-00585-5","volume":"26","author":"P Luo","year":"2020","unstructured":"Luo, P. et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol. Oncol. Res. POR 26(2), 599\u2013603 (2020).","journal-title":"Pathol. Oncol. Res. POR"},{"issue":"1","key":"77332_CR13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/j.gastro.2009.08.076","volume":"138","author":"JA Marrero","year":"2010","unstructured":"Marrero, J. A. & Feng, Z. Alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 138(1), 400\u2013401 (2010).","journal-title":"Gastroenterology"},{"issue":"13","key":"77332_CR14","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3748\/wjg.v25.i13.1550","volume":"25","author":"PS Harris","year":"2019","unstructured":"Harris, P. S. et al. Hepatocellular carcinoma surveillance: an evidence-based approach. World J. Gastroenterol. 25(13), 1550\u20131559 (2019).","journal-title":"World J. Gastroenterol."},{"issue":"2\u20133","key":"77332_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cytogfr.2004.01.005","volume":"15","author":"HG Wisniewski","year":"2004","unstructured":"Wisniewski, H. G. & Vilcek, J. Cytokine-induced gene expression at the crossroads of innate immunity, inflammation and fertility: TSG-6 and PTX3\/TSG-14. Cytokine Growth Factor Rev. 15(2\u20133), 129\u2013146 (2004).","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"77332_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1189\/jlb.1005557","volume":"79","author":"B Bottazzi","year":"2006","unstructured":"Bottazzi, B. et al. The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility. J. Leukoc. Biol. 79(5), 909\u2013912 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"77332_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-immunol-030409-101305","volume":"28","author":"B Bottazzi","year":"2010","unstructured":"Bottazzi, B., Doni, A., Garlanda, C. & Mantovani, A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 28, 157\u2013183 (2010).","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"77332_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.smim.2013.05.002","volume":"25","author":"A Inforzato","year":"2013","unstructured":"Inforzato, A. et al. PTX3 as a paradigm for the interaction of pentraxins with the complement system. Semin. Immunol. 25(1), 79\u201385 (2013).","journal-title":"Semin. Immunol."},{"key":"77332_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev.immunol.23.021704.115756","volume":"23","author":"C Garlanda","year":"2005","unstructured":"Garlanda, C., Bottazzi, B., Bastone, A. & Mantovani, A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 23, 337\u2013366 (2005).","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"77332_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1189\/jlb.0905493","volume":"79","author":"A Doni","year":"2006","unstructured":"Doni, A. et al. Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-gamma. J. Leukoc. Biol. 79(4), 797\u2013802 (2006).","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"77332_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1152\/physrev.00016.2017","volume":"98","author":"C Garlanda","year":"2018","unstructured":"Garlanda, C., Bottazzi, B., Magrini, E., Inforzato, A. & Mantovani, A. PTX3, a humoral pattern recognition molecule, in innate immunity, tissue repair, and cancer. Physiol. Rev. 98(2), 623\u2013639 (2018).","journal-title":"Physiol. Rev."},{"key":"77332_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3389\/fimmu.2019.00712","volume":"10","author":"A Doni","year":"2019","unstructured":"Doni, A. et al. The long pentraxin PTX3 as a link between innate immunity, tissue remodeling, and cancer. Frontiers Immunol. 10, 712 (2019).","journal-title":"Frontiers Immunol."},{"issue":"32","key":"77332_CR23","doi-asserted-by":"publisher","first-page":"32309","DOI":"10.18632\/oncotarget.4845","volume":"6","author":"E Bonavita","year":"2015","unstructured":"Bonavita, E., Mantovani, A. & Garlanda, C. PTX3 acts as an extrinsic oncosuppressor. Oncotarget 6(32), 32309\u201332310 (2015).","journal-title":"Oncotarget"},{"issue":"4","key":"77332_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.immuni.2014.02.015","volume":"40","author":"S Jaillon","year":"2014","unstructured":"Jaillon, S. et al. The humoral pattern recognition molecule PTX3 is a key component of innate immunity against urinary tract infection. Immunity 40(4), 621\u2013632 (2014).","journal-title":"Immunity"},{"issue":"2","key":"77332_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.18632\/oncotarget.1664","volume":"5","author":"B Choi","year":"2014","unstructured":"Choi, B. et al. Elevated Pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function. Oncotarget 5(2), 481\u2013492 (2014).","journal-title":"Oncotarget"},{"issue":"5","key":"77332_CR26","first-page":"2663","volume":"35","author":"B Choi","year":"2015","unstructured":"Choi, B. et al. Pentraxin-3 silencing suppresses gastric cancer-related inflammation by inhibiting chemotactic migration of macrophages. Anticancer Res. 35(5), 2663\u20132668 (2015).","journal-title":"Anticancer Res."},{"issue":"8","key":"77332_CR27","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1158\/1078-0432.CCR-10-3024","volume":"17","author":"EP Diamandis","year":"2011","unstructured":"Diamandis, E. P., Goodglick, L., Planque, C. & Thornquist, M. D. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 17(8), 2395\u20132399 (2011).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"3","key":"77332_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/bjc.2013.348","volume":"109","author":"S Kondo","year":"2013","unstructured":"Kondo, S. et al. Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. Br. J. Cancer 109(3), 739\u2013746 (2013).","journal-title":"Br. J. Cancer"},{"issue":"16","key":"77332_CR29","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1158\/0008-5472.CAN-14-0369","volume":"74","author":"G Stallone","year":"2014","unstructured":"Stallone, G. et al. Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. Can. Res. 74(16), 4230\u20134238 (2014).","journal-title":"Can. Res."},{"key":"77332_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1471-230X-8-53","volume":"8","author":"M Yoneda","year":"2008","unstructured":"Yoneda, M. et al. Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol. 8, 53 (2008).","journal-title":"BMC Gastroenterol."},{"issue":"9","key":"77332_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1089\/met.2015.0046","volume":"13","author":"S Boga","year":"2015","unstructured":"Boga, S. et al. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH. Metab. Syndrome Relat. Disord. 13(9), 393\u2013399 (2015).","journal-title":"Metab. Syndrome Relat. Disord."},{"issue":"3","key":"77332_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/MEG.0b013e32835ac77a","volume":"25","author":"DG Craig","year":"2013","unstructured":"Craig, D. G. et al. Elevated levels of the long pentraxin 3 in paracetamol-induced human acute liver injury. Eur. J. Gastroenterol. Hepatol. 25(3), 359\u2013367 (2013).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"3","key":"77332_CR33","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/hep.29215","volume":"66","author":"L Perea","year":"2017","unstructured":"Perea, L. et al. Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury. Hepatology 66(3), 953\u2013968 (2017).","journal-title":"Hepatology"},{"key":"77332_CR34","doi-asserted-by":"publisher","first-page":"2639248","DOI":"10.1155\/2019\/2639248","volume":"2019","author":"J Gorka-Dynysiewicz","year":"2019","unstructured":"Gorka-Dynysiewicz, J., Pazgan-Simon, M. & Zuwala-Jagiello, J. Pentraxin 3 detects clinically significant fibrosis in patients with chronic viral hepatitis C. Biomed. Res. Int. 2019, 2639248 (2019).","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"77332_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/jvh.12472","volume":"23","author":"RF Carmo","year":"2016","unstructured":"Carmo, R. F. et al. Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV. J. Viral Hepatitis 23(2), 116\u2013122 (2016).","journal-title":"J. Viral Hepatitis"},{"issue":"15","key":"77332_CR36","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.7150\/jca.25188","volume":"9","author":"T Song","year":"2018","unstructured":"Song, T., Wang, C., Guo, C., Liu, Q. & Zheng, X. Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition. J. Cancer 9(15), 2650\u20132658 (2018).","journal-title":"J. Cancer"},{"issue":"2","key":"77332_CR37","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, & European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, & European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67(2), 370\u2013398 (2017).","journal-title":"J. Hepatol."},{"issue":"6","key":"77332_CR38","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1053\/j.gastro.2008.02.090","volume":"134","author":"HB El-Serag","year":"2008","unstructured":"El-Serag, H. B., Marrero, J. A., Rudolph, L. & Reddy, K. R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134(6), 1752\u20131763 (2008).","journal-title":"Gastroenterology"},{"issue":"10","key":"77332_CR39","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100(10), 698\u2013711 (2008).","journal-title":"J. Natl Cancer Inst."},{"issue":"1","key":"77332_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/imr.12476","volume":"274","author":"K Daigo","year":"2016","unstructured":"Daigo, K. et al. Pentraxins in the activation and regulation of innate immunity. Immunol. Rev. 274(1), 202\u2013217 (2016).","journal-title":"Immunol. Rev."},{"issue":"6","key":"77332_CR41","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.jhep.2016.02.029","volume":"64","author":"B Bottazzi","year":"2016","unstructured":"Bottazzi, B. et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J. Hepatol. 64(6), 1416\u20131427 (2016).","journal-title":"J. Hepatol."},{"issue":"1","key":"77332_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbcan.2017.11.004","volume":"1869","author":"A Giacomini","year":"2018","unstructured":"Giacomini, A., Ghedini, G. C., Presta, M. & Ronca, R. Long pentraxin 3: A novel multifaceted player in cancer. Biochimica et biophysica acta Rev. Cancer 1869(1), 53\u201363 (2018).","journal-title":"Biochimica et biophysica acta Rev. Cancer"},{"key":"77332_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/978-3-0348-0837-8_16","volume":"816","author":"A Bishayee","year":"2014","unstructured":"Bishayee, A. The role of inflammation and liver cancer. Adv. Exp. Med. Biol. 816, 401\u2013435 (2014).","journal-title":"Adv. Exp. Med. Biol."},{"issue":"5","key":"77332_CR44","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.4049\/jimmunol.150.5.1804","volume":"150","author":"GW Lee","year":"1993","unstructured":"Lee, G. W., Lee, T. H. & Vilcek, J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J. Immunol. 150(5), 1804\u20131812 (1993).","journal-title":"J. Immunol."},{"issue":"10","key":"77332_CR45","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12275-015-5314-y","volume":"53","author":"CM Dinney","year":"2015","unstructured":"Dinney, C. M. et al. Regulation of HBV-specific CD8(+) T cell-mediated inflammation is diversified in different clinical presentations of HBV infection. J. Microbiol. 53(10), 718\u2013724 (2015).","journal-title":"J. Microbiol."},{"issue":"2","key":"77332_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/jir.2012.0093","volume":"33","author":"R Saxena","year":"2013","unstructured":"Saxena, R., Chawla, Y. K., Verma, I. & Kaur, J. Interleukin-1 polymorphism and expression in hepatitis B virus-mediated disease outcome in India. J. Interferon Cytokine Res. 33(2), 80\u201389 (2013).","journal-title":"J. Interferon Cytokine Res."},{"issue":"5","key":"77332_CR47","first-page":"737","volume":"139","author":"R Saxena","year":"2014","unstructured":"Saxena, R., Chawla, Y. K., Verma, I. & Kaur, J. Association of interleukin-10 with hepatitis B virus (HBV) mediated disease progression in Indian population. Indian J. Med. Res. 139(5), 737\u2013745 (2014).","journal-title":"Indian J. Med. Res."},{"issue":"5","key":"77332_CR48","doi-asserted-by":"publisher","first-page":"e0154815","DOI":"10.1371\/journal.pone.0154815","volume":"11","author":"H Xue","year":"2016","unstructured":"Xue, H. et al. Overrepresentation of IL-10-expressing B cells suppresses cytotoxic CD4+ T cell activity in HBV-induced hepatocellular carcinoma. PLoS ONE 11(5), e0154815 (2016).","journal-title":"PLoS ONE"},{"issue":"1","key":"77332_CR49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/path.2314","volume":"215","author":"A Savchenko","year":"2008","unstructured":"Savchenko, A. et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J. Pathol. 215(1), 48\u201355 (2008).","journal-title":"J. Pathol."},{"issue":"6","key":"77332_CR50","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","volume":"154","author":"K Tzartzeva","year":"2018","unstructured":"Tzartzeva, K. et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 154(6), 1706-1718.e1 (2018).","journal-title":"Gastroenterology"},{"key":"77332_CR51","first-page":"8906023","volume":"2018","author":"J Chen","year":"2018","unstructured":"Chen, J., Wu, G. & Li, Y. Evaluation of serum des-gamma-carboxy prothrombin for the diagnosis of hepatitis B virus-related hepatocellular carcinoma: a meta-analysis. Dis. Markers 2018, 8906023 (2018).","journal-title":"Dis. Markers"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77332-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77332-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77332-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T22:31:37Z","timestamp":1697149897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77332-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["77332"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-77332-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"11 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20276"}}